Mo
MorphoSys (Novartis)
Munich DEFounded 1992600 employees
Private CapbiotechAcquiredOncologyHematology
Platform: Ylanthia
Market Cap
N/A
All Drugs
3
Clinical Trials
5
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| MOR-7494 | MOR-7494 | Phase 1 | 2 | SMN2 | EoEFSGS | ||
| MOR-923 | MOR-923 | Preclinical | 1 | CD123 | CML | ||
| MOR-3625 | MOR-3625 | NDA/BLA | 2 | GIP-R | Ovarian CaCervical Ca |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (5)